<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1927">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04555941</url>
  </required_header>
  <id_info>
    <org_study_id>N202003022</org_study_id>
    <nct_id>NCT04555941</nct_id>
  </id_info>
  <brief_title>The Effects of Intermittent Theta Burst Stimulation in MCI and Early AD</brief_title>
  <official_title>Cognitive Effects of Theta Burst Stimulation in Mild Cognitive Impairment and Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Medical University Shuang Ho Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Medical University Shuang Ho Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcranial magnetic stimulation (TMS) is a noninvasive brain stimulation technique that is&#xD;
      increasingly used for a growing number of research and clinical applications.Typically, this&#xD;
      transient magnetic field is focally applied with a figure-of-eight coil that is carefully&#xD;
      placed on the surface of the scalp over a targeted stimulation site. Patterned repetitive TMS&#xD;
      (rTMS), such as theta burst stimulation (TBS) can produce long-lasting effects on neural&#xD;
      activity and behavior beyond the stimulation period (Chou et al., 2015a; Fitzgerald et al.,&#xD;
      2006). In general, high frequency (&gt; 5 Hz) rTMS and its newer version, intermittent theta&#xD;
      burst stimulation (iTBS), facilitate cortical excitability, whereas low frequency (about 1&#xD;
      Hz) rTMS and continuous theta burst stimulation contribute to opposite effects (Pascual-Leone&#xD;
      et al., 2000; Huang et al., 2005; Wassermann and Zimmermann, 2012).Careful manipulation of&#xD;
      the parameters comprising these patterned rTMS pulse trains can induce neuroplastic changes&#xD;
      that resemble either long-term potentiation (LTP) or depression (Chen et al., 1997;&#xD;
      Pascual-Leone et al., 1994). Early studies targeting the motor cortex helped elucidate which&#xD;
      rTMS parameters promote particular responses and their neurophysiological underpinnings&#xD;
      (Klomjai et al., 2015).&#xD;
&#xD;
      In recent years, rTMS has been closely investigated to evaluate its potential to modulate&#xD;
      cognitive functions in Alzheimer'sdisease (AD) and mild cognitive impairment (MCI). As&#xD;
      compared to conventional excitatory rTMS protocols, iTBS leads to comparable effects with&#xD;
      similar number of pulses but considerable shorter duration and lower intensity of stimulation&#xD;
      (Bakker et al., 2015; Rossi, Hallett, Rossini, Pascual-Leone, &amp; Safety, 2009). Recent&#xD;
      literature also suggest that TBS has lower rates of reported adverse event (AE) compared to&#xD;
      rTMS (Najib &amp; Horvath, 2014). Therefore, iTBS is assumed to modulate cognitive function in&#xD;
      people with cognitive impairments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Visit 1: Informed Consent, Brain MRI/Neuropsychological Battery&#xD;
&#xD;
      Visit 2-11: (up to a week after visit 1) iTBS - or Sham-Treatment (10 sessions, 80% Resting&#xD;
      Motor Threshold, 2s stimulation 8s inter-stimulus interval per train, 20 trains per block, 3&#xD;
      blocks per session with a 5-min break, 1 session per day)&#xD;
&#xD;
      Visit 12: (1 day or same day after visit 11) Functional Brain MRI/Neuropsychological Battery&#xD;
&#xD;
      Visit 13: (4 weeks after visit 11) Functional Brain MRI/Neuropsychological Battery&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 5, 2020</start_date>
  <completion_date type="Actual">January 31, 2022</completion_date>
  <primary_completion_date type="Actual">January 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The participant and principal investigator do not know what treatment is applied. The outcomes assessor will also be blinded. Only the co-PI who perform the TMS will know the stimulation condition.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in scores of any tests of the Neuropsychological Battery</measure>
    <time_frame>Baseline, immediate post-iTBS, follow-up (4 weeks post-iTBS)</time_frame>
    <description>WAIS-IV short-form, Word Sequence Learning Test, Benton Visual Retention Test, Color Trial Tests, 3-D Dimensional Constructional Test, Visual Confrontation Naming, Semantic Verbal Fluency Test, Stroop Color-Word Test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain MRI</measure>
    <time_frame>Baseline, immediate post-iTBS, follow-up (4 weeks post-iTBS)</time_frame>
    <description>Change in white matter and brain activities at resting state at baseline compared to after iTBS stimulation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Alzheimer Disease</condition>
  <condition>Cognitive Decline</condition>
  <arm_group>
    <arm_group_label>active iTBS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient is treated with iTBS stimulation according to protocol with an active coil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham iTBS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The patient is treated with Sham-iTBS stimulation according to protocol with an inactive coil.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>intermittent theta burst stimulation</intervention_name>
    <description>active or Sham iTBS will be given to the AD/MCI patient</description>
    <arm_group_label>Sham iTBS</arm_group_label>
    <arm_group_label>active iTBS</arm_group_label>
    <other_name>Magstim rapid 2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  normal visual acuity&#xD;
&#xD;
          -  diagnosed with mild cognitive impairment or early dementia due to Alzheimer's disease&#xD;
             (CDR = 0.5) by neurologists&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (family) history of seizure attacks&#xD;
&#xD;
          -  in intensive care&#xD;
&#xD;
          -  history of drug/alcohol dependence&#xD;
&#xD;
          -  assistants or students of the PI&#xD;
&#xD;
          -  major systemic diseases concerning cognitive decline (e.g., cardiopulmonary failure,&#xD;
             liver/renal failure, poor controlled DM, traumatic brain injury, stroke, or other&#xD;
             neurodegenerative diseases)&#xD;
&#xD;
          -  claustrophobia&#xD;
&#xD;
          -  metal implants&#xD;
&#xD;
          -  taking medication lowering the threshold of seizure attacks&#xD;
&#xD;
          -  fear of using TMS&#xD;
&#xD;
          -  with specific allergens&#xD;
&#xD;
          -  pregnant or breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-Chun Kuan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Medical University Shuang Ho Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shuang Ho Hospital</name>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>October 24, 2022</last_update_submitted>
  <last_update_submitted_qc>October 24, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taipei Medical University Shuang Ho Hospital</investigator_affiliation>
    <investigator_full_name>Cheng-Chang Yang</investigator_full_name>
    <investigator_title>Medical researcher</investigator_title>
  </responsible_party>
  <keyword>Transcranial magnetic stimulation</keyword>
  <keyword>non-invasive brain stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

